Anavex Life Sciences Corp. (NASDAQ:AVXL) announced that its oral pipeline drug candidate 2-73, developed to potentially modify Alzheimer’s disease rather than just temporarily …
In a research report published Monday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc (NASDAQ:CYTX), with a $5.00 …
Biotech firm Sophiris Bio Inc (NASDAQ:SPHS) just posted second-quarter results as well as an update on its progress for its clinical development program. …
Maxim analyst Jason Kolbert offers commentary on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the biotech firm reported its second-quarter results and …
Maxim analyst Jason Kolbert remains bullish on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the oncology drug maker just made waves signing a licensed agreement …
Maxim analyst Jason Kolbert reiterates a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) following an announcement of first patient enrollment in …
In a research note sent to investors Friday, Maxim analyst Jason Kolbert reiterated a Hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD), after the company announced …
In a research report published Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while raising the price …
In a research report issued Wednesday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), with a …
In a research report released Monday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), with a …
